Boehringer Ingelheim’s Nerandomilast Achieves Second Phase III Success in Pulmonary Fibrosis Treatment

Nerandomilast, Boehringer Ingelheim, Phase III trial, FIBRONEER-ILD, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, lung function, forced vital capacity

Boehringer Ingelheim’s Nerandomilast Succeeds in Second Phase III Lung Fibrosis Trial, Paving Way for FDA Approval

Nerandomilast, Boehringer Ingelheim, Phase III trial, FIBRONEER-ILD, progressive fibrosing interstitial lung diseases (PF-ILDs), lung function improvement, FDA approval, phosphodiesterase 4B (PDE4B) inhibitor

Fourth Patient Receives Gene-Edited Pig Kidney in Groundbreaking Clinical Trial

xenotransplantation, clinical trial, gene-edited pig kidney, FDA approval, United Therapeutics, eGenesis, end-stage renal disease, organ shortage